The FDA released guidance on the agency’s BsUFA II fee structure Thursday finalizing the changes introduced since BsUFA I — including that biosimilars will no longer be assessed supplemental or establishment fees and the number of program fees per year will be limited to five per company.
Source: Drug Industry Daily